Haemophilia

Hemophilia B Pipeline Insight Report 2024: Comprehensive Analysis of Emerging Therapeutics - ResearchAndMarkets.com

Retrieved on: 
tisdag, mars 5, 2024
Pharmaceutical, Health, Cardiology, Knowledge, Bleeding, Factor IX, Haemophilia B, Catalog, Genetic disorder, Research, Patient, Haemophilia, Pharmaceutical industry

The "Hemophilia B - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hemophilia B - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering.
  • Significant advances in the treatment and management of Hemophilia B are forthcoming, according to a new comprehensive research publication now available on our website.
  • The global coverage within this report transcends geographical boundaries, providing a universal perspective on the research and development efforts aimed at combatting Hemophilia B.
  • The report elucidates the complexity of Hemophilia B diagnosis and underscores the importance of comprehensive blood coagulation tests.

The Inner Circle acknowledges Amir A. Rasheed as a Distinguished Healthcare Professional

Retrieved on: 
torsdag, mars 7, 2024
Houston Methodist West Hospital, Inner circle, Iron-deficiency anemia, Multimedia, Houston Methodist Baytown Hospital, Hematology, Blood, North Shore University Hospital, Dow Medical College, SUNY Downstate Medical Center, St Luke's, State university system, Prognosis, Haemophilia, Internal medicine, Leukemia, Patient, Oncology, Medicine, Multiple myeloma, Medical Center, Diagnosis, Anti-transglutaminase antibodies, Lymphoma, Cancer, Hospital

SUGARLAND, Texas, March 7, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Amir A. Rasheed is acknowledged as a Distinguished Healthcare Professional for his contributions to the fields of Oncology and Hematology.

Key Points: 
  • SUGARLAND, Texas, March 7, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Amir A. Rasheed is acknowledged as a Distinguished Healthcare Professional for his contributions to the fields of Oncology and Hematology.
  • Dr. Rasheed pursued his medical education at Dow Medical College where he earned a medical degree.
  • He then relocated to the United States to complete a residency in internal medicine at the State University of New York Health Science Center at Brooklyn.
  • Known for his compassionate care and clinical excellence, Dr. Rasheed has dedicated his life to delivering the highest standard of quality care to his patients.

BioMarin Announces Appointment of Cristin Hubbard as Chief Commercial Officer

Retrieved on: 
torsdag, mars 7, 2024
Cristin, SAN, School, Ophthalmology, Roche, Growth, Public health, MBA, Molecular biology, Postgraduate education, University, Haemophilia, Business, BioMarin Pharmaceutical, Triple accreditation, Patient, Infection, BMRN

SAN RAFAEL, Calif., March 7, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that Cristin Hubbard has been named executive vice president and chief commercial officer. Ms. Hubbard will assume responsibility for the company's global commercial operations, effective May 20, succeeding Jeff Ajer.

Key Points: 
  • SAN RAFAEL, Calif., March 7, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that Cristin Hubbard has been named executive vice president and chief commercial officer.
  • Ms. Hubbard will assume responsibility for the company's global commercial operations, effective May 20, succeeding Jeff Ajer.
  • Ms. Hubbard is a proven leader who brings to BioMarin more than 20 years of experience in the biopharmaceutical and diagnostics industries.
  • He has worked at BioMarin for more than 18 years, including 11 as chief commercial officer.

Cloud Peritus and Junction Health Forge Strategic Salesforce Partnership

Retrieved on: 
måndag, mars 4, 2024
Cloud, SAN, Crohn's disease, SVP, Health, Data management, Growth, Multiple sclerosis, Salesforce, Rheumatoid arthritis, CRM, Haemophilia, Patient, Partnership, Nursing

SAN RAMON, Calif., March 4, 2024 /PRNewswire/ -- Cloud Peritus, a renowned expert in cloud technology announces an exciting collaboration with Junction Health, a leading provider of healthcare infusion services.

Key Points: 
  • SAN RAMON, Calif., March 4, 2024 /PRNewswire/ -- Cloud Peritus, a renowned expert in cloud technology announces an exciting collaboration with Junction Health, a leading provider of healthcare infusion services.
  • Cloud Peritus will be instrumental in helping Junction Health develop a strategic roadmap of Salesforce CRM capabilities, and optimizing the value of their investment in the platform.
  • "We're thrilled to work with Cloud Peritus to leverage a host of integrated solutions on the Salesforce platform.
  • Together, Junction Health and Cloud Peritus are poised to deliver unparalleled value to patient and provider stakeholders and drive sustainable growth for its community health center partners.

Dynamic Access Launches Dynamic Infusion, a Specialty Home Infusion Nursing Provider

Retrieved on: 
onsdag, februari 28, 2024
Multiple sclerosis, Patient, Crohn's disease, Organization, Pharmacy, Haemophilia, Rheumatoid arthritis

DALLAS, Feb. 28, 2024 /PRNewswire/ -- Dynamic Access, LLC (Dynamic Access), a leading provider of vascular access solutions, has announced the launch of a new affiliate brand, Dynamic Infusion, which will provide home infusion nursing services for patients with chronic conditions such as autoimmune disorders, hemophilia, Crohn's disease, rheumatoid arthritis, multiple sclerosis and more.

Key Points: 
  • DALLAS, Feb. 28, 2024 /PRNewswire/ -- Dynamic Access, LLC (Dynamic Access), a leading provider of vascular access solutions, has announced the launch of a new affiliate brand, Dynamic Infusion, which will provide home infusion nursing services for patients with chronic conditions such as autoimmune disorders, hemophilia, Crohn's disease, rheumatoid arthritis, multiple sclerosis and more.
  • The Dynamic Infusion brand will support the operations of two legacy companies, each with more than a decade of experience delivering home infusion nursing services to patients throughout the Northeast: Infusion Ventures in New England, and NursePro in the Mid-Atlantic.
  • Peter Harris, CEO of Dynamic Access will also serve as CEO of Dynamic Infusion.
  • "The recent addition of NursePro expands our portfolio of specialty nursing solutions, expands our geographical footprint, and expands the number of lives we serve with life-changing care."

Half year reported NPATA US$2 billion¹,² Up 13% at constant currency³

Retrieved on: 
tisdag, februari 13, 2024
Acquisition, Warfarin, CSL Behring, Depreciation, Research, Ministry, Messenger, CIDP, Marketing, CSL, Growth, Plasmapheresis, Primary immunodeficiency, Von Willebrand disease, Antibody, S&M, Immunodeficiency, ASX, Income tax, Haemophilia, HAE, Ministry of Health, CSL Vifor, Hereditary angioedema, Plasma, COVID, Patient, Webcast, Phase, Diagnosis, G&A, CC3, Pressure, CSL Limited, Vaccine

MELBOURNE, Australia, Feb. 13, 2024 /PRNewswire/ -- CSL Limited (ASX:CSL; USOTC:CSLLY) today announces a reported net profit after tax of $1.90 billion1 for the 6 months ended 31 December 2023, up 20% on a constant currency basis3. Underlying profit (NPATA) was $2.02 billion1,2, up 13% on a constant currency basis to $2.06 billion1,2,3.

Key Points: 
  • Underlying profit (NPATA) was $2.02 billion1,2, up 13% on a constant currency basis to $2.06 billion1,2,3.
  • Immunoglobulin (Ig) product sales of $2,757 million, increased 23%3 with strong growth recorded across all geographies driven by global plasma supply and patient demand.
  • HIZENTRA® (Immune Globulin Subcutaneous (Human), 20% Liquid) sales were up 18%3 driven by  patient diagnosis rates.
  • However, due to the seasonality of this business we anticipate it to post a loss in the second half of the fiscal year.

Half year reported NPATA US$2 billion¹,² Up 13% at constant currency³

Retrieved on: 
tisdag, februari 13, 2024
Acquisition, Warfarin, CSL Behring, Depreciation, Research, Ministry, Messenger, CIDP, Marketing, CSL, Growth, Plasmapheresis, Primary immunodeficiency, Von Willebrand disease, Antibody, S&M, Immunodeficiency, ASX, Income tax, Haemophilia, HAE, Ministry of Health, CSL Vifor, Hereditary angioedema, Plasma, COVID, Patient, Webcast, Phase, Diagnosis, G&A, CC3, Pressure, CSL Limited, Vaccine

MELBOURNE, Australia, Feb. 13, 2024 /PRNewswire/ -- CSL Limited (ASX:CSL; USOTC:CSLLY) today announces a reported net profit after tax of $1.90 billion1 for the 6 months ended 31 December 2023, up 20% on a constant currency basis3. Underlying profit (NPATA) was $2.02 billion1,2, up 13% on a constant currency basis to $2.06 billion1,2,3.

Key Points: 
  • Underlying profit (NPATA) was $2.02 billion1,2, up 13% on a constant currency basis to $2.06 billion1,2,3.
  • Immunoglobulin (Ig) product sales of $2,757 million, increased 23%3 with strong growth recorded across all geographies driven by global plasma supply and patient demand.
  • HIZENTRA® (Immune Globulin Subcutaneous (Human), 20% Liquid) sales were up 18%3 driven by  patient diagnosis rates.
  • However, due to the seasonality of this business we anticipate it to post a loss in the second half of the fiscal year.

Iambic Therapeutics Expands Leadership Team With the Appointment of Neil Josephson, MD as Chief Medical Officer

Retrieved on: 
fredag, februari 9, 2024
Oncology, Health, Technology, Health Technology, Artificial Intelligence, Biotechnology, Iamb, FDA, Therapy, Associate, Drug discovery, University, Hematology, Multiple myeloma, Columbia University, Haemophilia, Dartmouth College, Multimedia, Division, Patient, Faculty, Antibody, CMO, Doctor of Philosophy, HER2, Nursing

Iambic Therapeutics, a biotechnology company developing novel therapeutics using its AI-driven discovery platform, today announced the appointment of oncologist and industry veteran Neil Josephson, M.D., as its Chief Medical Officer (CMO).

Key Points: 
  • Iambic Therapeutics, a biotechnology company developing novel therapeutics using its AI-driven discovery platform, today announced the appointment of oncologist and industry veteran Neil Josephson, M.D., as its Chief Medical Officer (CMO).
  • Under his leadership zanidatamab achieved FDA Breakthrough Therapy designation for previously-treated HER2 gene-amplified biliary tract cancer, with a subsequent positive readout of a registrational study for the same indication.
  • Prior to Zymeworks, he was vice president of clinical development at Seagen, working across early and late-stage candidates for programs in Hodgkin Lymphoma and multiple myeloma.
  • Dr. Josephson received his medical degree at Columbia University and earned his undergraduate degree at Dartmouth College.

Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and

Retrieved on: 
fredag, februari 9, 2024
Society, PWH, Pharmacokinetics, Part, Safety, Haemophilia, ASH, CNTA, APC, Male, Patient, Person, Pharmaceutical industry

The Company previously shared Part 5 results during a poster presentation at the 65th American Society of Hematology (ASH) Annual Meeting.

Key Points: 
  • The Company previously shared Part 5 results during a poster presentation at the 65th American Society of Hematology (ASH) Annual Meeting.
  • SerpinPC is an investigational subcutaneously administered novel inhibitor of activated protein C (APC) in registrational studies for the treatment for hemophilia B, with or without inhibitors.
  • “EAHAD provides an exciting opportunity to highlight the therapeutic potential of SerpinPC,” said Saurabh Saha MD PhD, Chief Executive Officer of Centessa.
  • “The compelling data from the ongoing Phase 2a study further demonstrate the potential for SerpinPC to be a convenient subcutaneous treatment with a differentiated safety profile for people living with hemophilia.

BioMarin to Present ROCTAVIAN™ (valoctocogene roxaparvovec-rvox) Data Highlighting Long-Term Durability at 2024 European Association for Haemophilia and Allied Disorders (EAHAD) Congress

Retrieved on: 
tisdag, februari 6, 2024
Injection, SAN, BioMarin Pharmaceutical, Congress, Hemostasis, Safety, ABR, Central European Time, Bleeding, Risk, Haemophilia, Pharmaceutical industry

SAN RAFAEL, Calif., Feb. 6, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today announced that new data on ROCTAVIAN™ (valoctocogene roxaparvovec-rvox) will be presented at the 2024 European Association for Haemophilia and Allied Disorders (EAHAD) Congress, Feb. 6-9, 2024.

Key Points: 
  • SAN RAFAEL, Calif., Feb. 6, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today announced that new data on ROCTAVIAN™ (valoctocogene roxaparvovec-rvox) will be presented at the 2024 European Association for Haemophilia and Allied Disorders (EAHAD) Congress, Feb. 6-9, 2024.
  • The majority of participants maintained hemostasis, with only two of the seven participants in the study returning to regular prophylaxis, and no new safety signals emerged.
  • These data will be presented as a poster presentation from 6:30-7:30 p.m. Central European Time (CET) on Wednesday, Feb. 7.
  • "We are pleased to present data showing the impact of one-time treatment with ROCTAVIAN over seven years following the infusion, underscoring the potential of gene therapy to make a meaningful and long-lasting impact for people living with severe hemophilia A."